Skip to main content

Market Overview

FDA Approves Use Of Zika Virus Blood Screener From Hologic And Grifols


Hologic Inc (NASDAQ: HOLX) and Grifols, S.A. (NASDAQ: GRFS) announced Monday that they won FDA approval for the use of the Procleix Zika virus blood screening assay.

U.S. blood centers will use Procleix to screen blood donations in the Southern US and other areas potentially affected by the virus. The American Red Cross has partnered with Hologic and Grifols to perform the Procleix Zika Virus assay investigational study.

Hologic and Grifols shares closed Monday at $34.14 and $15.58, respectively, both up about 1 percent from Friday's close.


Related Articles (HOLX + GRFS)

View Comments and Join the Discussion!

Posted-In: Zika Zika VirusBiotech News Health Care FDA Media General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at